Zobrazeno 1 - 10
of 11
pro vyhledávání: '"T Lobaton Ortega"'
Autor:
S Deleu, C Caenepeel, S Verstockt, J F Vazquez Castellanos, K Arnauts, S Braekeleire, K Machiels, F Baert, F Mana, L Pouillon, P Hindryckx, T Lobaton Ortega, E Louis, D Franchimont, B Verstockt, M Ferrante, J Sabino, S Vieira-Silva, G Falony, J Raes, S Vermeire
Publikováno v:
Journal of Crohn's and Colitis. 17:i1029-i1031
Background The efficacy of faecal microbiota transplantation (FMT) in UC has been reported to be donor-, patient- and procedure-dependent (Rees et al., 2022). The RESTORE-UC trial [NCT03110289] aimed to improve the outcome of FMT in patients with act
Autor:
Marie Truyens, Niels Teich, Gabriele Dragoni, Edoardo Savarino, Idan Goren, T. Lobaton Ortega, Annalisa Aratari, Ariella Bar-Gil Shitrit, Stefano Festa, Frank Hoentjen, Rafał Filip, M Chaparro, María García, I Krela-Kaźmierczak, Javier P. Gisbert, R.L.J. van Wanrooij, Ioannis E. Koutroubakis, Davide Giuseppe Ribaldone, Christianne J. Buskens, Tamás Molnár, Uri Kopylov, Lauranne A A P Derikx, H Laja, Claudio Papi, M Argollo, E.J.M. Nieveen van Dijkum, F Panzuto, H Reiss, Iris D. Nagtegaal, Kalliopi Foteinogiannopoulou, Daniela Pugliese, E Vainer, Giulia Zerboni
Publikováno v:
Journal of Crohn's and Colitis. 15:S215-S216
Background Neuroendocrine Neoplasms (NENs) are a heterogeneous group of tumours deriving from the diffuse endocrine system. NENs may occur almost everywhere in the body but are most common in the gastrointestinal tract, the pancreas, and the lungs, w
Autor:
M Truyens, Jeroen Geldof, G Dewitte, Elien Glorieus, Dirk Elewaut, G Varkas, T. Lobaton Ortega
Publikováno v:
Journal of Crohn's and Colitis. 14:S546-S547
Background Vedolizumab (VDZ), a gut-specific anti-integrin, is approved as a treatment for moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). Extra-intestinal manifestations (EIMs) are frequently associated with inflammatory bowel
Autor:
T. Lobaton Ortega, T. Bessissow, G. De Hertogh, G. Van Assche, S. Vermeire, P. Rutgeerts, R. Bisschops, A. Bitton, W. Afif, M. Ferrante
Publikováno v:
Journal of Crohn's and Colitis. 8:S113-S114
Autor:
C Arajol, Francisco Rodríguez-Moranta, Lorena Rodríguez-Alonso, Josep Martin-Comin, S. Maisterra, E. Sanchez Pastor, Alexandra Ruiz-Cerulla, Jordi Guardiola, O. Puig-Calvo, T. Lobaton Ortega
Publikováno v:
Journal of Crohn's and Colitis. 8:S177-S178
Autor:
Vera Ballet, G. Van Assche, Marc Ferrante, T. Lobaton Ortega, Paul Rutgeerts, Severine Vermeire
Publikováno v:
Journal of Crohn's and Colitis. 8:S273
Autor:
E. Duenas, Jordi Guardiola, Francisco Rodríguez-Moranta, Lorena Rodríguez, A. Lopez-Garcia, X. San Juan, A. Ruiz, T. Lobaton Ortega, L. Carolina
Publikováno v:
Journal of Crohn's and Colitis. 7:S104
Clinical Institute. Among them 237 patients had diarrhea: ulcerative colitis (UC) 116 patients, Crohn’s disease (CD) 38, chronic pancreatitis (CP) 58, others 26 (IBS, coeliac disease, colon cancer). All UC and CD patients received AB in the past th
Autor:
Francisco Rodríguez-Moranta, E. Duenas, Jordi Guardiola, T. Lobaton Ortega, C. Parra Cancino, L. Rodriguez Alonso
Publikováno v:
Journal of Crohn's and Colitis. 6:S176
Background: CDI is the main cause of antibiotic associated infectious diarrhea. Incidence, severity and burden on the healthcare system related to CDI have increased in last decade in many industrialized countries. Epidemiological data of CDI are sca
Autor:
Francisco Rodríguez-Moranta, L. Rodriguez Alonso, E. Sanchez-Pastor, A. Lopez-Garcia, S. Ruiz-Cerulla, Jordi Guardiola, T. Lobaton Ortega
Publikováno v:
Journal of Crohn's and Colitis. 6:S81
(p = 0.5). Appendectomy is an important factor in CD (p = 0.001, OR = 1 1.2). Smoking is not significant in our series (p = 0.4). 96% of patients in both groups had no family history of IBD. CD patients are significantly more hospitalized compared to
Autor:
E. Sanchez-Pastor, A. Lopez-Garcia, S. Maistrerra, Jordi Guardiola, L. Rodriguez Alonso, Francisco Rodríguez-Moranta, T. Lobaton Ortega
Publikováno v:
Journal of Crohn's and Colitis. 6:S91
tertiary IBD center were reviewed. Inclusion criteria: (1) Small bowel CD assessed by conventional techniques; (2) Detailed clinical history; (3) No stenosis/obstructions; (4) Small bowelCD assessed by entero-CT/-MRI, small intestinal contrast ultras